BANGKOK, Nov. 28, 2022 /PRNewswire/ — COLOTECT is a non-invasive colorectal cancer (CRC) self-sampling test that can detect the methylation status of exfoliated cell genes in the intestine, help screen for colorectal cancer and precancerous lesions risk, and detect bowel cancer risk even in the absence of active bleeding lesions, according to BkkGI.
Colorectal cancer is the third most common cancer and the second deadliest cancer globally. In 2020, the number of colorectal cancer diagnoses worldwide was about 1.9 million.
Older age, a history of bowel disease, a family history of related diseases, having type 2 diabetes, being overweight or obese, certain types of diet, smoking, and drinking are all risk factors that can lead to colorectal cancer. In recent years, the incidence rate of colorectal cancer among young people has also been increasing significantly.
As the tumor grows, patients may experience one or multiple symptoms, including blood in the stool, abdominal pain, and bloating, among others.
However, colorectal cancer usually does not show any symptoms in the early stages, which causes nearly 50% of patients not be detected until they reach the third or fourth stage and miss the best time for treatment. If colorectal cancer is diagnosed at a early stage, the 5-year relative survival rate of patients can be as high as 90%. Conversely, if it is stage IV at the time of discovery, the 5-year survival rate will be reduced to only about 10%.
Click here to learn about the new method of early screening for colorectal cancer. https://youtu.be/6RVq57jAK8o
A non-invasive, painless, convenient , and the best way to deal with colorectal cancer is to actively use COLOTECT and other screening methods to detect and treat colorectal cancer as early as possible.
